Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Dementia patients want effective drugs. How will the FDA respond?

Ron Louie, MD
Meds
May 16, 2018
Share
Tweet
Share

Dementia patients want effective drugs. Five years ago, the Food and Drug Administration (FDA) proposed changes to speed drug approvals for Alzheimer’s disease (AD). No new drugs have been approved. This year, a new FDA draft guidance discusses considering biomarker data and changing cognitive evaluations for accelerated approvals. Would that help make effective drugs available, or are we lowering our expectations?

Numerous dementia agents have failed current improvement standards in trials, which require positive changes in both cognitive and functional measures. One hypothesis about the failures is that symptomatic patients are poorly salvageable, so a better target might be earlier stages of dementia. The new guidance suggests a specific staging system for early AD. The earliest stage subjects would have measurable “Alzheimer’s biomarkers” but no measurable cognitive or functional symptoms.

Since such subjects don’t have measurable symptoms to impact, drugs demonstrating biomarker improvement alone might be eligible for accelerated approval, with a requirement for studies “to confirm the predicted clinical benefit.”

Accelerated approval isn’t necessary to conduct such efficacy studies; it almost would seem that drug payers would be helping to fund them.

Bapineuzumab, an amyloid therapy, changed neuroimaging and spinal fluid biomarkers in symptomatic AD patients, but failed to meet improvement criteria for approval. Adverse effects such as hippocampal atrophy are still being interpreted . Solanezumab, another amyloid agent, had an effect on biomarkers but also failed. The guidance seems to suggest that these agents could be considered for accelerated approval in asymptomatic persons if further “persuasive” results were presented.

Interestingly, the document states that currently “there is no consensus as to particular biomarkers that would be appropriate to support clinical findings in trials in early AD,” and that “the certainty of their [the subjects’ ] future clinical course” must still be established.

Interpreting those statements, the FDA is not yet satisfied with the current documentation of progression in early AD. If progression is not well defined, how does one know if a drug is effective in preventing Alzheimer’s disease?

The FDA document discusses why the current dual criteria may not be appropriate. The guidance encourages improving current cognitive measures in a “meaningful” way. This begs the question of whether the dual measures are protecting symptomatic patients from ineffective drugs or keeping them from drugs that might be effective.

In this context, it is interesting to look at Avastin’s accelerated approval (2009) for another intractable brain disease, the malignant tumor progressive glioblastoma multiforme (GBM). Avastin’s first FDA label stated: “Effectiveness based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival with Avastin” . Response rate included neuroimaging, notoriously problematic in GBM . (Alzheimer biomarkers include neuroimaging).

Only recently, combination chemotherapy trials that included Avastin showed several months benefit in progression free survival (PFS), with no change in overall survival; that evidently helped full approval . Years of earlier studies were not convincing. It is still not recommended for frontline therapy, and is not considered curative.

Some consider PFS a surrogate measure. There were adverse events associated with Avastin and impacts on quality of life in the study. A dilemma for us oncologists prescribing drugs like Avastin is gauging whether they really help patients or just “prolong dying.” A similar dilemma would confront dementia physicians if new agents are approved with FDA labels similar to that above, which seems possible from the draft guidance.

What one wants from FDA approval is a drug that has a reasonable chance of a discernible good effect, with tolerable safety. Ironically, the FDA allows television marketing of “brain supplements,” readily available over the counter, even dog food for canine cognitive issues. Of course, the agency has different standards for those categories, mainly safety, not efficacy.

The FDA seems to be taking a directive leadership role here, throwing down some challenges. Perhaps the new recommendations will spur development that will provide therapies for all stages of AD, so that one day we will have something that “really works,” even if we may have to lower our expectations for now.

ADVERTISEMENT

Ron Louie is a pediatric oncologist.

Image credit: Shutterstock.com

Prev

Blockchain technology can dramatically transform health care delivery

May 16, 2018 Kevin 6
…
Next

Nurses made this doctor who she is today

May 16, 2018 Kevin 9
…

Tagged as: Neurology

Post navigation

< Previous Post
Blockchain technology can dramatically transform health care delivery
Next Post >
Nurses made this doctor who she is today

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

More by Ron Louie, MD

  • Will Alzheimer’s disease researchers miss seeing the forest from the trees?

    Ron Louie, MD
  • Do substituted decisions break the Golden Rule?

    Ron Louie, MD
  • Interpreting 2 recent studies involving Alzheimer disease

    Ron Louie, MD

Related Posts

  • Are patients using social media to attack physicians?

    David R. Stukus, MD
  • You are abandoning your patients if you are not active on social media

    Pat Rich
  • The FDA was wrong about Aduhelm

    M. Bennet Broner, PhD
  • A love letter to patients

    Marcie Costello
  • Patients are not passengers

    Christopher Noll, RN, MSN
  • Expensive Medicare patients aren’t who you think

    Peter Ubel, MD

More in Meds

  • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

    Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO
  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • The hidden bias in how we treat chronic pain

    Richard A. Lawhern, PhD
  • Biologics are not small molecules: the case for pre-allergy testing in an era of immune-based therapies

    Robert Trent
  • The anesthesia spectrum: Guiding patients through comfort options in oral surgery

    Dexter Mattox, MD, DMD
  • Most Popular

  • Past Week

    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • Why recovery after illness demands dignity, not suspicion

      Trisza Leann Ray, DO | Physician
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
    • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

      Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO | Meds
    • How conflicts of interest are eroding trust in U.S. health agencies [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Make cognitive testing as routine as a blood pressure check

      Joshua Baker and James Jackson, PsyD | Conditions
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • The broken health care system doesn’t have to break you

      Jessie Mahoney, MD | Physician
  • Recent Posts

    • How conflicts of interest are eroding trust in U.S. health agencies [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why young doctors in South Korea feel broken before they even begin

      Anonymous | Education
    • Measles is back: Why vaccination is more vital than ever

      American College of Physicians | Conditions
    • When errors of nature are treated as medical negligence

      Howard Smith, MD | Physician
    • Physician job change: Navigating your 457 plan and avoiding tax traps [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden chains holding doctors back

      Neil Baum, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • Why recovery after illness demands dignity, not suspicion

      Trisza Leann Ray, DO | Physician
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
    • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

      Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO | Meds
    • How conflicts of interest are eroding trust in U.S. health agencies [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Make cognitive testing as routine as a blood pressure check

      Joshua Baker and James Jackson, PsyD | Conditions
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • The broken health care system doesn’t have to break you

      Jessie Mahoney, MD | Physician
  • Recent Posts

    • How conflicts of interest are eroding trust in U.S. health agencies [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why young doctors in South Korea feel broken before they even begin

      Anonymous | Education
    • Measles is back: Why vaccination is more vital than ever

      American College of Physicians | Conditions
    • When errors of nature are treated as medical negligence

      Howard Smith, MD | Physician
    • Physician job change: Navigating your 457 plan and avoiding tax traps [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden chains holding doctors back

      Neil Baum, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Dementia patients want effective drugs. How will the FDA respond?
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...